Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity.The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 18.99%. Akorn's revenue for the same period is $227.26 million.The trailing-twelve-month return on equity at Hi Tech Pharmacal Co (NASDAQ: HITK) is 18.38%. Hi Tech Pharmacal's operating margin for the same period is 24.58%.The trailing-twelve-month return on equity at Salix Pharmaceuticals (NASDAQ: SLXP) is 15.84%. Salix Pharmaceuticals had $775.90 million in total cash for the latest quarter.The trailing-twelve-month return on equity at Mylan (NASDAQ: MYL) is 14.65%. Mylan's PEG ratio is 0.72.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!